Atherosclerosis

Anthera gets U.S. FDA approval to begin phase II PLASMA trial for atherosclerosis

Published in Healthcare Mergers, Acquisitions and Ventures Week, February 3rd, 2007

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for its lead cardiovascular compound A-002.

As a result of this approval, Anthera will initiate a multicenter phase II clinical trial (PLASMA - Phospholipase Levels And Serological Markers of Atherosclerosis) that will examine the effect of A-002 on secretory phospholipase A2 (sPLA2) levels and other well established markers of inflammation and cardiovascular risk in patients with stable coronary artery disease due to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week

Source: Healthcare Mergers, Acquisitions and Ventures Week (2007-02-03)

More Articles from Healthcare Mergers, Acquisitions and Ventures Week

Adverse Drug Reactions
Scientists at AstraZeneca detail research in adverse drug reactions in children
Alzheimer Disease
Allon receives approval for phase II clinical trial in Alzheimer-related condition
Analytical Chemistry
New analytical chemistry study findings have been reported from Merck & Co, Inc.
Angiogenesis
New angiogenesis study findings recently were published by researchers at ImClone Systems, Inc.
Animal Cloning
U.S. FDA issues draft documents on safety of animal clones
Anthrax Vaccines
Studies from Medarex, Inc. describe new findings in anthrax vaccines
More from this issue of Healthcare Mergers, Acquisitions and Ventures Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry